Amakem Therapeutics

Amakem is an ophthalmology company developing new treatments for severe eye diseases. Amakem's product pipeline is based on its unique localized drug action platform, which is designed to generate safe and effective novel kinase inhibitors while minimizing systemic exposure to reduce side effects. Amakem’s lead candidate, AMA0076, is for the treatment of glaucoma, and the company is working to apply the localized drug action approach to a range of other eye conditions.